share_log

Moderna | 10-Q: Q3 2024 Earnings Report

Moderna | 10-Q: Q3 2024 Earnings Report

Moderna | 10-Q:2024財年三季報
美股SEC公告 ·  2024/11/08 06:11

Moomoo AI 已提取核心訊息

Moderna reported Q3 2024 revenue of $1.8 billion, including $1.8 billion in product sales primarily from COVID-19 vaccines and initial RSV vaccine sales. The company achieved net income of $13 million or $0.03 per share, compared to a net loss of $3.6 billion in Q3 2023. Cost of sales decreased significantly to $514 million or 28% of net product sales, down from 128% in the prior year period.The company's financial position remains strong with $9.2 billion in cash and investments as of September 30, 2024. Operating expenses showed improvement with research and development costs decreasing 2% to $1.1 billion and selling, general and administrative expenses declining 36% to $281 million compared to Q3 2023, reflecting enhanced operational efficiency and cost discipline.Looking ahead, Moderna expects continued transition to a seasonal commercial model for COVID-19 vaccines while expanding its product portfolio with the recent RSV vaccine launch. The company is advancing multiple late-stage clinical programs including next-generation COVID-19, seasonal flu, CMV and norovirus vaccines, as well as its individualized neoantigen therapy program in collaboration with Merck.
Moderna reported Q3 2024 revenue of $1.8 billion, including $1.8 billion in product sales primarily from COVID-19 vaccines and initial RSV vaccine sales. The company achieved net income of $13 million or $0.03 per share, compared to a net loss of $3.6 billion in Q3 2023. Cost of sales decreased significantly to $514 million or 28% of net product sales, down from 128% in the prior year period.The company's financial position remains strong with $9.2 billion in cash and investments as of September 30, 2024. Operating expenses showed improvement with research and development costs decreasing 2% to $1.1 billion and selling, general and administrative expenses declining 36% to $281 million compared to Q3 2023, reflecting enhanced operational efficiency and cost discipline.Looking ahead, Moderna expects continued transition to a seasonal commercial model for COVID-19 vaccines while expanding its product portfolio with the recent RSV vaccine launch. The company is advancing multiple late-stage clinical programs including next-generation COVID-19, seasonal flu, CMV and norovirus vaccines, as well as its individualized neoantigen therapy program in collaboration with Merck.
Moderna報告了2024年第三季度的營業收入爲$18億,包括來自COVID-19生物-疫苗和初始RSV生物-疫苗銷售的$18億產品銷售。該公司實現了凈利潤爲$1300萬,或者每股$0.03,而2023年第三季度則出現了$36億的淨虧損。銷售成本大幅下降至$51400萬,佔淨產品銷售的28%,而去年同期爲128%。截至2024年9月30日,該公司的財務狀況依然強勁,現金和投資達到$92億。營業費用有所改善,研發費用下降了2%,降至$11億,而銷售、一般和行政費用相比2023年第三季度下降了36%,降至$28100萬,反映出提升的運營效率和成本控制。展望未來,Moderna預計COVID-19生物-疫苗將持續向季節性商業模式轉型,同時通過最近的RSV生物-疫苗發佈擴展其產品組合。該公司正在推進多個晚期臨牀項目,包括下一代COVID-19、生物-疫苗、季節性流感、CMV和諾如病毒生物-疫苗,以及與默沙東合作的個性化新抗原療法項目。
Moderna報告了2024年第三季度的營業收入爲$18億,包括來自COVID-19生物-疫苗和初始RSV生物-疫苗銷售的$18億產品銷售。該公司實現了凈利潤爲$1300萬,或者每股$0.03,而2023年第三季度則出現了$36億的淨虧損。銷售成本大幅下降至$51400萬,佔淨產品銷售的28%,而去年同期爲128%。截至2024年9月30日,該公司的財務狀況依然強勁,現金和投資達到$92億。營業費用有所改善,研發費用下降了2%,降至$11億,而銷售、一般和行政費用相比2023年第三季度下降了36%,降至$28100萬,反映出提升的運營效率和成本控制。展望未來,Moderna預計COVID-19生物-疫苗將持續向季節性商業模式轉型,同時通過最近的RSV生物-疫苗發佈擴展其產品組合。該公司正在推進多個晚期臨牀項目,包括下一代COVID-19、生物-疫苗、季節性流感、CMV和諾如病毒生物-疫苗,以及與默沙東合作的個性化新抗原療法項目。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息